As the only available triple agonist, it enables simultaneous investigation of three metabolic receptor pathways in one experiment
For patients with severe or persistent GI symptoms, temporary dose reduction or holding the GLP-1 medication (under clinician guidance) may be considered
Natural hunger and fullness signals
Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
Because Ozempic is originally a diabetic medication, many patients looking to use it for weight loss will likely have to pay out of pocket
Yes, with adjusted doses and regular monitoring
